 This is an open-label, multicenter, global Phase 2 basket study of entrectinib RXDX-101 for the treatment of patients with solid tumors that harbor an NTRK123, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. 